The drugmaker announced topline results from its phase 1 trial of its Amycretin pill on March 7, and following the announcement, Novo Nordisk shares jumped 7.5%, according to The Wall Street Journal.
In the trial, patients taking Amycretin lost about 13% of their body weight in 12 weeks — more than double the weight lost during the same time period with Wegovy, which was about 6%.
The pill is taken once daily and is slated to head into phase 2 trials later this year, the Journal reported. However, Barclays analysts wrote in a note that Novo Nordisk has “not ruled out going [straight] into Phase 3 development,” with the drug.
In addition to the pill, Novo Nordisk also noted it has about 10 other obesity treatments currently in development.
